Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Algernon Pharmaceuticalsinc (CSE:AGN)

0.0700 -0.0050 (-6.67%)
Streaming Delayed Price Updated: 1:43 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Algernon Pharmaceuticalsinc

'Wall Street God' Who Made A 100x Return On COVID Market Crash Doesn't Dare Bet Against This Industry
There may not be an investor anywhere who played the March 2020 COVID-induced market crash more deftly than Bill Ackman.  
Via Benzinga
AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.  
Via Benzinga
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an ... 
Via Benzinga
#Artificial Intelligence in Healthcare - Sim&Cure Announces the Appointment of Dan Raffi as Chief Operating Officer and Board Member
#Artificial Intelligence in Healthcare - Sim&Cure Announces the Appointment of Dan Raffi as Chief Operating Officer and Board Member 
Via News Direct
Topics Artificial Intelligence
CHAPTER AESTHETIC STUDIO LAUNCHES SECOND LOCATION WITH NEW STUDIO IN NEW HARTFORD, NY
With plans to scale nationwide, Chapter Aesthetic Studio is poised to launch a dozen locations in the next year, disrupting the medical aesthetics industry 
Via News Direct
FDA Expands Allergan's BOTOX Label To Include Eight New Muscles In Patients With Upper Limb Spasticity
The 
Via Benzinga
Allergan Shares Updated Data From Vision Loss Candidate Showing Significant Improvement In Near-Vision Reading
Allergan, a unit of AbbVie Inc (NYSE: ABBV), has announced new data, including the full results from the Phase 3 GEMINI 1 study of AGN-190584 (pilocarpine 1.25%)... 
Via Benzinga
Can Evolus Disrupt the Botox Market?
This small-cap stock is going after a billion-dollar market. 
Via The Motley Fool
New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.